Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry

Circulation Journal

Volumn 74, Issue 11, 2010, Pages 2314-2321

  Hahn, Joo Yong ^a   Song, Young Bin ^a   Choi, Jin Ho ^a   Choi, Sung Hyuk ^a   Lee, Sung Yun ^b   Park, Hun Sik ^c   Hur, Seung Ho ^d   Lee, Sahng ^e   Han, Kyoo Rok ^f   Rha, Seung Woon ^g   Cho, Byung Ryul ^h   Park, Jong Sun ⁱ   Yoon, Junghan ^j   Lim, Do Sun ^k   Lee, Sang Hoon ^a   Gwon, Hyeon Cheol ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inje University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Eulji University School of Medicine   (South Korea)

^f Hallym University   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h Kangwon National University   (South Korea)

ⁱ Young Nam University Hospital   (South Korea)

^j Wonju Severance Christian Hospital   (South Korea)

^k Korea University College of Medicine   (South Korea)

more..

Author keywords

Antiplatelets; Drug eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ZOTAROLIMUS;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; POPULATION RISK; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78349250911     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0347     Document Type: Article

References (27)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
3. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.
4. Pfisterer M, Brunner-la Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591
5. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimuseluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
6. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295.
7. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754.
8. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-168.
9. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
10. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based casecontrol study. BMJ 2006; 333: 726.
11. Iwata Y, Kobayashi Y, Fukushima K, Kitahara H, Asano T, Ishio N, et al. Incidence of premature discontinuation of antiplatelet therapy after sirolimus-eluting stent implantation. Circ J 2008; 72: 340-341.
12. Leon MB, Mauri L, O'Shaughnessy C, Ovelie PA, McLaurin BT, Solomon SL, et al. Late safety and efficacy of a Zotarolimus- Eluting stent compared with a Paclitaxel-Eluting stent in patients with de novo coronary lesions: Three-year follow-up from the ENDEAVOR IV Trial (abstract). Am J Cardiol 2009; 104: 150D.
13. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83: 338-345.
14. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: 36M-44M.
15. Kim JS, Jang IK, Fan C, Kim TH, Kim JS, Park SM, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimuseluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009; 2: 1240-1247.
16. Kim JS, Jang IK, Kim JS, Kim TH, Takano M, Kume T, et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: Comparison with sirolimus-eluting stents. Heart 2009; 95: 1907-1912.
17. Kim JW, Seo HS, Park JH, Na JO, Choi CU, Lim HE, et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: Differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009; 53: 1653-1659.
18. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
19. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
20. Banerjee S, Varghese C, Samuel J, Weideman RA, Little BB, Kelly KC, et al. Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol 2008; 102: 1159-1162.
21. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
22. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
23. Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, et al. Zotarolimus-eluting stents in patients with native coronary artery disease: Clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007; 100: 45M-55M.
24. Jain AK, Meredith IT, Lotan C, Rothman MT, Pateraki S. Realworld safety and efficacy of the endeavor zotarolimus-eluting stent: Early data from the E-Five Registry. Am J Cardiol 2007; 100: 77M-83M.
25. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, et al. Long-term follow-up of neointimal coverage of sirolimus- eluting stents: Evaluation with optical coherence tomography. Circ J 2009; 73: 2300-2307.
26. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, et al. Delayed neointimalization on sirolimus-eluting stents: 6- month and 12-month follow up by optical coherence tomography. Circ J 2009; 73: 1033-1037.
27. Kim JS, Kim JS, Kim TH, Fan C, Lee JM, Kim W, et al. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxeleluting stents using optical coherence tomography at 9 months after implantation. Circ J 2010; 74: 320-326.